Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis

• Autores: Meltem Zeytinoglu, Sandra C. Naaman, Laura T. Dickens
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 50, Nº. 2, 2021 (Ejemplar dedicado a: Updates on Osteoporosis), págs. 205-222
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Denosumab (DMAB) is a potent antiresorptive treatment used for treatment of osteoporosis and low bone mineral density (BMD) in those at high risk for fracture. In postmenopausal women with osteoporosis, DMAB treatment for 10 years has been studied, with results showing continued gains in BMD, sustained fracture risk reduction, and low risk of adverse events. However, upon discontinuation of DMAB, there is a rapid reversal of effect, with increase in bone turnover, loss of BMD, and in a subset of patients, a greater risk for multiple vertebral fractures.